ATLANTA, Ga., March 30 -- Lasertec International, Inc. has secured a financing commitment of $40 million from Lilly Beter Capital Group, Ltd. The Company says the money will fund new product rollout and offset the expense of the Federal Drug Administration approval process of laser-based cancer diagnostic and treatment devices. Lasertec has patented a dye laser system called the Photo Therapy Resonance System to destroy cancer cells without damaging surrounding healthy tissue.